1183 HX111, a FIC OX40-mAb-VC-MMAE ADC for the treatment of lymphoma

Tao Yang, Hang Ke, Feiyu Peng, Jialin Li, Cen Chen, Lei Zhang, Faming Zhang, Henry LiRegular 2025 · DOI

Introduction

Lymphomas, particularly Adult T-cell Leukemia (ATL) and Angioimmunoblastic T-cell Lymphoma (AITL), continue to present significant therapeutic challenges due to poor prognoses and resistance to conventional treatments. While the OX40 receptor (TNFR4) is a well-established co-stimulatory molecule on activated T-cells, its role as a direct surface target on malignant lymphoma cells has remained largely under-exploited. Traditional therapeutic strategies targeting OX40 have focused on agonism—stimulating the immune system to attack the tumor. However, this research introduces HX111, a first-in-class antibody-drug conjugate (ADC) designed to utilize OX40 as a homing beacon for the direct delivery of cytotoxic payloads to cancer cells.

Design and Mechanism of Action

HX111 is composed of a high-affinity, non-blocking monoclonal antibody (mAb) conjugated to the potent microtubule inhibitor monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline (VC) linker.

Key structural features include:

  • Targeting Specificity: The mAb binds to an epitope on OX40 that does not interfere with the binding of its natural ligand (OX40L). This non-blocking characteristic is critical for promoting efficient cellular internalization.
  • Payload Delivery: With an average drug-to-antibody ratio (DAR) of 4, HX111 ensures a consistent delivery of MMAE. The VC linker remains stable in systemic circulation but is rapidly cleaved by lysosomal enzymes once the ADC is internalized by the target lymphoma cell.
  • Bystander Effect: HX111 exhibits a robust bystander effect. Upon the death of an OX40-positive cell, the released MMAE can permeate the membranes of neighboring OX40-negative malignant cells, addressing the challenge of intratumoral heterogeneity.

Experimental Methodology

The efficacy of HX111 was evaluated through a comprehensive suite of in vitro and in vivo assays:

  • Internalization and Cytotoxicity: Studies were conducted using OX40-expressing cell lines, including HuT-102, HuT-78, and Jurkat, to assess the rate of ADC uptake and subsequent cell death.
  • Pharmacological Modeling: The researchers employed both Cell Line-Derived Xenografts (CDX) and Patient-Derived Xenografts (PDX). The CDX models included HuT-102 and HuT-78 (ATL), GRANTA-519 (Mantle Cell Lymphoma), and ARH-77 (Plasma Cell Lymphoma). The PDX models encompassed four Diffuse Large B-cell Lymphoma (DLBCL) variants and one AITL model.

Key Results

Potent In Vitro Activity

HX111 demonstrated superior cytotoxicity against OX40-positive lymphoma cells compared to standard OX40-mAbs. The success of the ADC was closely tied to its rapid internalization kinetics, which allowed for the efficient accumulation of MMAE within the target cells.

Broad In Vivo Efficacy

In preclinical models, HX111 induced significant, dose-dependent anti-tumor activity across all nine xenograft models tested. This efficacy spanned a diverse range of lymphoma subtypes, including T-cell and B-cell malignancies. Notably, the degree of tumor regression did not always correlate linearly with OX40 expression levels, suggesting that factors such as internalization rates and inherent sensitivity to MMAE are also critical determinants of therapeutic response.

Combination Therapy Potential

The study also explored the synergistic potential of HX111. In a B-lymphoma PDX model, the combination of HX111 with HX009—a bispecific antibody targeting PD-1 and SIRPα—resulted in enhanced anti-tumor effects. This suggests that HX111 could serve as a foundational component of multi-modal immunotherapy regimens.

Discussion and Future Directions

HX111 represents a paradigm shift in OX40-targeted therapy, moving from immune modulation to direct cytotoxic targeting. By successfully treating a wide array of lymphoma models, including those resistant to current standards of care, HX111 has established itself as a promising clinical candidate.

Future research will focus on identifying predictive biomarkers to better select patients likely to respond to HX111, as OX40 expression alone is not the sole predictor of efficacy. Additionally, clinical trials will be necessary to evaluate the safety profile of HX111, particularly its impact on healthy activated T-cells that also express OX40. Given its potent anti-tumor activity and ability to overcome tumor heterogeneity via the bystander effect, HX111 warrants further investigation in a clinical setting.

Summary updated

BibTeX
@inproceedings{yang2025hx,
  author = {Tao Yang and Hang Ke and Feiyu Peng and Jialin Li and Cen Chen and Lei Zhang and Faming Zhang and Henry Li},
  title = {{1183 HX111, a FIC OX40-mAb-VC-MMAE ADC for the treatment of lymphoma}},
  booktitle = {Regular},
  year = {2025},
  doi = {10.1136/jitc-2025-sitc2025.1183},
}
Figure